RecruitingPhase 2

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

United States192 participantsStarted 2025-12-11

Plain-language summary

The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ≥ 75 years of age;
✓. Chronic lung disease that is symptomatic and requiring chronic treatment; and
✓. Chronic cardiovascular disease that is symptomatic and requiring chronic treatment.

What they're measuring

Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2

Timeframe: Baseline, Day 2

Change From Baseline in RSV RNA Load by qRT-PCR (Nasopharyngeal Swab) at Day 4

Timeframe: Baseline, Day 4

Change From Baseline in RSV RNA Load by qRT-PCR (Nasopharyngeal Swab) at Day 6

Timeframe: Baseline, Day 6

Trial details

NCT IDNCT07214571

SponsorShionogi

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12-30

Contact for this trial

Shionogi Clinical Trials Administrator Clinical Support Help Line

800-849-9707 Shionogiclintrials-admin@shionogi.co.jp

View on ClinicalTrials.gov More Respiratory Syncytial Virus Infections trials